Global Hidradenitis Suppurativa COVID‐19 Registry: A Registry to Inform Data‐Driven Management Practices – Naik – – British Journal of Dermatology

The management of hidradenitis suppurativa (HS), a chronic inflammatory skin disease, deserves special consideration in the context of the Coronavirus 2019 (COVID‐19) pandemic. A new Global Hidradenitis Suppurativa COVID‐19 Registry has been developed to capture data on risks, clinical course, and outcomes of COVID‐19 in HS patients. Caused by the virus SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus‐2), COVID‐19 is an easily transmissible disease which, in its most severe form, is characterized by respiratory failure and multiple organ dysfunction triggered by a cytokine storm response that predominates in older adults and those with significant comorbidities.

Source link

Membertou man hopes his story can raise awareness about kidney health

Googoo was diagnosed with glomerulonephritis, an inflammation of tiny filters in the kidneys, and hidradenitis suppurativa, a chronic skin condition.

Source link

Top 5 Companies in Hidradenitis Suppurativa Market

Hidradenitis Suppurativa Market Latest Research Report 2020:

The Hidradenitis Suppurativa report provides an independent information about the Hidradenitis Suppurativa industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porter’s five force analysis, and key companies

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Hidradenitis Suppurativa Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth. 

Scope of Hidradenitis Suppurativa Market: Products in the Hidradenitis Suppurativa classification furnish clients with assets to get ready for tests, tests, and evaluations. 

Major Company Profiles Covered in This Report

Company I, Company II, Company III, Company IV and more

  • Key Highlights of the Hidradenitis Suppurativa Market Report : 
  1. 1Hidradenitis Suppurativa Market Study Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide Hidradenitis Suppurativa market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications. 
  2. Hidradenitis Suppurativa Market Executive outline:This area stresses the key investigations, market development rate, serioscene, market drivers, patterns, and issues notwithstanding the naturally visible pointers. 
  3. Hidradenitis Suppurativa Market Production by Region:The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now. 
  4. Hidradenitis Suppurativa Market Profile of Manufacturers:Analysis of each market player profiled is detailed in this section. This portion likewise provides SWOT investigation, items, generation, worth, limit, and other indispensable elements of the individual player. 
  • Some of the major objectives of this report:
  1. To provide a detailed investigation of the market structure alongside conjecture of the different sections and sub-portions of the worldwide Hidradenitis Suppurativa Market. 
  2. To provide bits of knowledge about factors influencing market development. To examine the Hidradenitis Suppurativa Market dependent on different variables value examination, store network investigation, porter five power investigation and so on. 
  3. To provide authentically and estimate the income of the Hidradenitis Suppurativa Market portions and sub-fragments concerning four principle geographies and their nations North America, Europe, Asia, and the Rest of the World. 
  4. Nation level examination of the market regarding the present market size and future prospective. 
  5. To provide a national level examination of the market for section by Component, Technology, Application, End-Use, And Region. 
  6. To provide key profiling of key players in the market, thoroughly investigating their center capabilities, and drawing a serioscene for the market. 
  7. Track and break down serioadvancements, for example, joint endeavors, key coalitions, mergers and acquisitions, new item improvements, and research and improvements in the worldwide Hidradenitis Suppurativa Market. 

Hidradenitis Suppurativa Market Report Covers the Following Segments:

Segment by Type:
Type I, Type II, Type III

Segment by Application:
Application I, Application II, Application III

  • Market Size Segmentation by Region & Countries (Customizable): 

North America



South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Hidradenitis Suppurativa Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Hidradenitis Suppurativa Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the global Hidradenitis Suppurativa Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Hidradenitis Suppurativa Market.

Market Statand Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Hidradenitis Suppurativa Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the global Hidradenitis Suppurativa Market.

Market Forecast: Here, the report offers a complete forecast of the global Hidradenitis Suppurativa Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

Source link

Hidradenitis Suppurativa Market Growth, Share, Trends 2020-Stimulus, Recovery Hopes May Boost Future| AbbVie, Novartis AG, Eisai Co., Abbott, Allergan, Johnson & Johnson Services, Merck & Co, Pfizer

Latest study released by Data Bridge Market Research on Global Hidradenitis Suppurativa Market research with more than 220 market data tables and figures spread through Pages are easy to understand TOC in “Global Hidradenitis Suppurativa Market research”, so you can get a variety of ways to maximize your profits. This Hidradenitis Suppurativa market report has been arranged by effectively using technology, new applications and expertise to manage large and complex market data tables and forecast automatically. In this market research report, a thorough SWOT analysis & investment analysis is provided which forecasts imminent opportunities for the market players. The report endows with precise and exact market research information including sound facts and figures which will drive the business in the right direction.

Get Exclusive Sample Report: To Know the Impact of COVID-19 on this [email protected] 


The COVID-19 Pandemic has created bottlenecks across industry pipelines, sales funnels, and supply chain activities. This has created unprecedented budget pressure on company spending for industry leaders. This has increased requirement for opportunity analysis, price trend knowledge and competitive outcomes. Use the DBMR team to create new sales channels and capture new markets previously unknown. DBMR helps its clients to grow in these uncertain markets.

Based on geography, North America represent high market share for global hidradenitis suppurativa market due to the established regulatory framework, high demand of diseases specific treatment, rise in adoption of newer technologies, presence of refined healthcare infrastructure and increased patient awareness level as well as high prevalence of hidradenitis suppurativa. Europe is considered a second largest growing regional segment owing to the presence of global marketed players in this region and surge in population. Asia Pacific leads the market due to the rise in number of generic manufacturers in this region as well as increasing disposable income.

The Segments And Sub-Section of Hidradenitis Suppurativa Market are shown below:

By Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3)

By Skin Condition (Folliculitis, Pimples, Boils, Deep-Acne, Others)

By Treatment Type (Surgery, Medications, Photodynamic Therapy (PDT), Laser Treatment, Others)

By Route of Administration (Oral, Parenteral, Others

By End-Users (Hospitals, Homecare, Speciality Centres, Others

By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Region Included are: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

Top Leaders in the Market are:
AbbVie Inc.
Novartis AG, Inc.
Eisai Co., Ltd
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc
Merck & Co., Inc
Pfizer Inc
Mylan N.V.
LEO Pharma A/S
Zydus Cadila
Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@ 

Hidradenitis Suppurativa Market report supports in defining and optimizing each stage in the lifecycle of industrial process that comprises engagement, acquisition, retention, and monetization. The analysis and estimations conducted via this Hidradenitis Suppurativa Market report help to get an idea about the product launches, future products, joint ventures, marketing strategy, developments, mergers and acquisitions and effect of the same on sales, marketing, promotions, revenue, import, export, and CAGR values. This market document is a brilliant guide for actionable ideas, enhanced decision-making and better business strategies. The insights given in this Hidradenitis Suppurativa Market research report are established upon SWOT analysis on which businesses can rely confidently.

Global Hidradenitis Suppurativa Market Scope and Market Size

Global hidradenitis suppurativa market is segmented on the basis of clinical stage, skin condition, treatment, route of administration end-users and distribution channel.

Based on clinical stage, the global hidradenitis suppurativa market is segmented into hurley stage
1, hurley stage 2 and hurley stage 3.

By mode of skin condition, the global hidradenitis suppurativa market has been segmented into folliculitis, pimples, boils, deep-acne and others.

Treatment type for the global hidradenitis suppurativa market is segmented into surgery, medications, photodynamic therapy (PDT), laser treatment and others. The medications segment has been sub-segmented into biologics, antibiotics, hormonal therapy, immunosuppressive drugs, zinc supplements, retinoids, pain medication and others.

The route of administration segment for global hidradenitis suppurativa market is segmented into oral, parenteral and others.

On the basis of end-users, the global hidradenitis suppurativa market is segmented into hospitals, homecare, speciality centres and others.

On the basis of distribution channel, the global hidradenitis suppurativa market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

(Final Report will add the analysis of the impact of COVID-19 on this industry.)

Buy the Latest Detailed Report @ 

Key questions answered

o What impact does COVID-19 have made on Hidradenitis Suppurativa Market Growth & Sizing?

o Who are the Leading key players and what are their Key Business plans in the Hidradenitis Suppurativa market?

o What are the key concerns of the five forces analysis of the Hidradenitis Suppurativa market?

o What are different prospects and threats faced by the dealers in the Hidradenitis Suppurativa market?

o What are the strengths and weaknesses of the key vendors?

Major Highlights of TOC:

Chapter One: Hidradenitis Suppurativa Market Industry Overview

1.1 Hidradenitis Suppurativa Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Hidradenitis Suppurativa Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Hidradenitis Suppurativa Market Demand

2.1 Segment Overview



2.1.3 Other

2.2 Hidradenitis Suppurativa Market Size by Demand

2.3 Hidradenitis Suppurativa Market Forecast by Demand

Chapter Three: Hidradenitis Suppurativa Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Hidradenitis Suppurativa Market Size by Type

3.3 Hidradenitis Suppurativa Market Forecast by Type

Chapter Four: Major Region of Hidradenitis Suppurativa Market

4.1 Hidradenitis Suppurativa Sales

4.2 Hidradenitis Suppurativa Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Our Upcoming Event: Future of Healthcare Robotics|Digital Conference

HEALTHCARE ROBOTICS is the upcoming future of Medical Sciences. The usage of robotics is already prevalent in surgeries across developed and emerging geographies. It has been quite a while where integration of robotics across healthcare supply chain is being discussed. The Covid – 19 Pandemic is expected to speed up the timeline for these innovations and concepts to become reality. With the requirement of telemedicine and robotics in handling samples the healthcare industry is expected to see a digital paradigm shift in the next 2 years. The point here to be discussed is where the future is for healthcare robotics Surgical, Diagnostics or Telemedicine.




In the pioneer edition of DBMR Healthcare Robotics Conference come join us in this enriching knowledge fest where experts will speak on new technologies and market dynamics perceptions. Together lets move ahead in the future of medical science and technology.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[email protected]

Source link

Increased Hypothyroidism Risk Seen in Young Men With HS

Young men with hidradenitis suppurativa are “surprisingly” at increased risk for hypothyroidism, Anna Figueiredo, MD, declared at the virtual annual meeting of the American Academy of Dermatology.

The surprise about this finding from a large retrospective case–control study stems from the fact that the elevated risk for hypothyroidism didn’t also extend to younger women with hidradenitis suppurativa (HS) nor to patients older than 40 years of either gender, explained Dr. Figueiredo of the department of dermatology at Northwestern University, Chicago.

She presented a retrospective case–control study based on information extracted from a medical records database of more than 8 million Midwestern adults. Among nearly 141,000 dermatology patients with follow-up in the database for at least 1 year, there were 405 HS patients aged 18–40 years and 327 aged 41–89.

In an age-matched comparison with the dermatology patients without HS, the younger HS cohort was at a significant 1.52-fold increased risk for comorbid hypothyroidism. Upon further stratification by sex, only the younger men with HS were at increased risk. Those patients were at 3.95-fold greater risk for having a diagnosis of hypothyroidism than were age-matched younger male dermatology patients.

Both younger and older HS patients were at numerically increased risk for being diagnosed with hyperthyroidism; however, this difference didn’t approach statistical significance because there were so few cases: a total of just eight in the HS population across the full age spectrum.

Hidradenitis suppurativa is a chronic inflammatory disease with an estimated prevalence of up to 4% in the United States. Growing evidence suggests it is an immune-mediated disorder because the tumor necrosis factor inhibitor adalimumab (Humira) has been approved for treatment of HS.

Thyroid disease is also often autoimmune-mediated, but its relationship with HS hasn’t been extensively examined. A recent meta-analysis of five case–control studies concluded that HS was associated with a 1.36-fold increased risk of thyroid disease; however, the Nepalese investigators didn’t distinguish between hypo- and hyperthyroidism (J Am Acad Dermatol. 2020 Feb;82[2]:491-3).

Dr. Figueiredo reported having no financial conflicts regarding her study, which was without commercial support.

American Academy of Dermatology (AAD) 2020 Annual Meeting.

This article originally appeared on

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Source link

Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Insights, Status, Latest Trends and Outlook CELGENE CORPORATION, Celltrion Inc., GlaxoSmithKline plc – Owned

tumor necrosis factor (TNF) inhibitor drugs market is expected to rise to an estimated value of USD 182.27 billion by 2026, registering a healthy CAGR in the forecast period of 2019-2026. Rising cases of Crohn’s disease and increasing demand for effective treatment are the major factor for the growth of this market.

Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market By Drug (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Pipeline Analysis), Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, Crohn’s Disease, Plaque Psoriasis, Ulcerative Colitis, Hidradenitis Suppurativa, Juvenile Arthritis, Uveitis, Others), Product (Humira, Enbrel, Remicade, Simponi, Cimzia), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Few of the major competitors currently working in the global tumor necrosis factor (TNF) inhibitor drugs market are AbbVie Inc., Ablyn, Aryogen Farmad, CASI Pharmaceuticals Inc., CELGENE CORPORATION, Celltrion Inc., GlaxoSmithKline plc, HanAll Biopharma, Janssen Global Services, LLC, Leo Pharma, LG Chem, AstraZeneca, Momenta Pharmaceuticals, Novartis AG, PROBIOMED S.A. de C.V., Samsung Bioepis, Sandoz International GmbH, Sanofi, Shanghai Pharmaceutical Group Co., Ltd., FUJIFILM Toyama Chemical Co., Ltd. among others.

Click to Get Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market Research Sample PDF Copy Here @

Market Definition: 

TNF inhibitors are drugs which are usually used to stop inflammation. They are widely used to treat diseases like rheumatoid, ulcerative, Crohn’s disease, ulcerative colitis, plaque psoriasis etc. They are usually made from the antibodies of human or animal tissues. These drugs are usually inserted in the blood so that they can create a reaction in immune system and stop inflammation. Increasing cases of Crohn’s disease is the major factor fueling the market growth.

Market Drivers

  • Rising cases of autoimmune disorders among population will drive the market growth
  • Increasing research and development activities in tumor necrosis factor (TNF) inhibitor drugs will also propel the growth of this market
  • Proper reimbursement policies also acts as a major driver for this market
  • Rising awareness among population about the benefits of TNF inhibitors can accelerate the market growth
  • Rising ageing population is also acting as a market driver

Market Restraints

  • Availability of alternative in market acts as a restricting factor in the growth of this market
  • High production cost of TNF drug also hampers the market growth


By Drug

  • Adalimumab
  • Certolizumab
  • Etanercept
  • Golimumab
  • Infliximab
  • Pipeline Analysis
    • Phase III Molecules
    • Phase I & Phase II Molecules

By Application

  • Rheumatoid Arthritis
  • Psoriasis
  • Inflammatory Bowel Disease
  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Plaque Psoriasis
  • Ulcerative Colitis
  • Hidradenitis Suppurativa
  • Juvenile Arthritis
  • Uveitis
  • Others

By Product

  • Humira
  • Enbrel
  • Remicade
  • Simponi
  • Cimzia

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • South America
    • Brazil
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific
  • Middle East & Africa
    • South Africa
    • Rest of Middle East & Africa

Enquire for customization in Report @

Key Developments in the Market:

  • In December 2018, Amgen and Entera Bio announced that they have collaborated so that they can create orally administered formulations of biologic drugs. As per the agreement, Entera will get access fee from Amgen and will do all the preclinical development Amgen’s expenses. This will help the companies to use their technology and strengthen them in the market
  • In April 2018, Promethera Biosciences announced that they have takeover Balipharm so that they can take control of TNF receptor 1 inhibitor so that they can increase their cell therapy NASH strategy. This acquisition will help them to combine HepaStem with an anti-TNF antibody and will act as an additional layer for their anti-inflammatory and anti-fibrotic approach

Competitive Analysis:

Global tumor necrosis factor (TNF) inhibitor drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of tumor necrosis factor (TNF) inhibitor drugs market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global tumor necrosis factor (TNF) inhibitor drugs market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Get Full TOC @

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]

Source link

Hidradenitis Suppurativa Diagnosis Not Found to Be Associated With Greater Stroke Risk

The following article is part of coverage from the American Academy of Dermatology’s Annual Meeting (AAD 2020). Because of concerns regarding the coronavirus disease 2019 (COVID-19) pandemic, all AAD 2020 sessions and presentations were transitioned to a virtual format. While live events will not proceed as planned, readers can click here to view more news related to research presented during the AAD VMX 2020 virtual experience.

A diagnosis of hidradenitis suppurativa (HS) was not found to be associated with a greater risk for stroke, although there was a trend for a greater risk in patients ≤60 years with vs without HS, according to study results presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2020, held online from June 12 to 14, 2020.

Although HS has been associated with a greater risk for adverse cardiovascular outcomes, the investigators noted, there is diverging evidence regarding the associated risk for stroke.

In this study, real-world data from dermatology patients from the Midwestern United States (US) were obtained from a medical record repository containing data from > 8 million individuals. The data of patients who had received a diagnosis of HS — based on International Classification of Diseases Ninth and Tenth Revision (ICD 9-10) codes 705.83 and L73.2, respectively — by a dermatologist between 2001 and 2018, were examined. Patients who were followed by a clinician for at least 1 month after diagnosis were included in the analysis. The control cohort consisted of dermatology patients who had not received an HS diagnosis during this time period. The study’s outcome of interest was a stroke diagnosis (hemorrhagic or ischemic, based on ICD 9-10 codes).

Of the 248,054 dermatology patients in this repository, 1324 received a diagnosis of HS. In this cohort, the risk for stroke was not found to be greater in patients with vs without an HS diagnosis (adjusted odds ratio [aOR], 1.23; 95% CI, 0.998-2.196; P =.26).

In patients aged 18 to 60 years (n=1223), but not in patients 61 to 89 years, the risk for stroke tended to be greater, although not reaching statistical significance, in patients with vs without an HS diagnosis (aOR, 1.59; 95% CI, 0.96-2.63; P =.069).

“Contrary to some prior reports, this large, urban Midwestern US dermatology patient population did not yield a significant association between HS and stroke (hemorrhagic and ischemic in aggregate) in either age cohort,” noted the study authors. “However, the trend toward significantly higher risk for stroke in patients [with HS] ≤ 60 years of age compared [with] same age of patients with no HS, has not been previously reported, suggesting that HS may play an independent role in the developing of stroke in this patient population.”


Parker JJ, Gwillim EC, Ali Y, Pease DR, Laumann AE, West DP, et al. Risk of hemorrhagic and ischemic stroke subsequent to diagnosis for hidradenitis suppurativa: real world data from a large urban Midwestern U.S. patient population. Presented at: AAD VMX 2020; June 12-14, 2020. Poster # 16834.

Source link

BRIEF-UCB Canada Says Data From Phase 3 Be Vivid, Be Ready Studies Show Bimekizumab-Treated Patients With Psoriasis Showed Significant Skin Clearance At Week 16

June 22 (Reuters) – UCB CANADA:







Source link

Increased Risk for Inflammatory Arthritis in Patients With Newly Diagnosed Hidradenitis Suppurativa

The following article is part of coverage from the American Academy of Dermatology’s Annual Meeting (AAD 2020). Because of concerns regarding the coronavirus disease 2019 (COVID-19) pandemic, all AAD 2020 sessions and presentations were transitioned to a virtual format. While live events will not proceed as planned, readers can click here to view more news related to research presented during the AAD VMX 2020 virtual experience.

Patients with a newly recorded diagnosis of hidradenitis suppurativa (HS) have increased risks for developing inflammatory arthritis, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), and rheumatoid arthritis (RA), according to study results presented at the American Academy of Dermatology’s Virtual Meeting Experience (AAD VMX) 2020, held online from June 12 to 14, 2020.

To evaluate and compare the risk for inflammatory arthritis in patients with vs without HS, researchers collected data from patients having commercial insurance in the United States, from January 1, 2003 to January 1, 2017. The study cohort included patients with newly diagnosed HS who were propensity score-matched 1:1 with control participants without HS with similar risk profiles. All participants were followed until 1 of the events, including primary outcome, death, disenrollment, or end of datastream, occurred. The main outcome of the study was a new diagnosis of inflammatory arthritis, including AS, PsA, other spondyloarthritis (SpA), or RA. Researchers conducted all statistical analyses using a validated version of the Aetion Evidence Platform.

Researchers identified 70,697 patients with HS (mean age, 36.54±14.65 years; 78.0% women) and 141,411 without HS (mean age, 38.29±21.12 years; 52.0% women) after 2:1 risk set sampling and before propensity score matching. Researchers also noted that patients did not have a range of chronic inflammatory and autoimmune conditions before cohort entry. Median follow-up for patients with and without HS was 527 and 539 days, respectively.

After propensity score matching, results showed that age, sex, healthcare utilization, and comorbidities were similar between both groups. Patients with vs without HS (n=60,872 for both) had a 65%, 44%, and 16% increased risk for AS, PsA, and RA, respectively (incidence rates, 0.6 vs 0.4, 0.8 vs 0.6, and 4.5 vs 3.9 per 1000 person-years; hazard ratios [HRs; 95% CI], 1.65 [1.15-2.35], 1.44 [1.08-1.93], and 1.16 [1.03-1.31], respectively). Researchers did not observe any association of HS with other SpA (HR, 1.02; 95% CI, 0.89-1.93), including reactive arthropathy, spinal enthesopathy, sacroiliitis, or unspecific inflammatory spondylopathies.

Researchers concluded, “Given the high burden of disease associated with both HS and arthritis, physicians treating patients with HS should be aware of symptoms suggestive of inflammatory arthritis (ie, morning stiffness, joint pain or swelling).”


Schneeweiss MC, Kim SC, Schneeweiss S, Rosmarin D, Merola JF. Hidradenitis suppurativa and the risk of inflammatory arthritis: a population-based follow-up study. Presented at: AAD VMX 2020; June 12-14, 2020. Poster 14344.

Source link

How Coronavirus is Impacting Hidradenitis Suppurativa Treatment, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026

COVID-19 Impact Analysis of Hidradenitis Suppurativa Treatment Market

[Los Angeles], [United States], June 2020,– – The Hidradenitis Suppurativa Treatment Market research report includes an in-sight study of the key [Global Hidradenitis Suppurativa Treatment Market Size, Status and Forecast 2020-2026]  market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the Hidradenitis Suppurativa Treatment report to gain a clear view of the competitive landscape and accordingly plan Hidradenitis Suppurativa Treatment market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Hidradenitis Suppurativa Treatment specifications, and company profiles. The Hidradenitis Suppurativa Treatment study is segmented by Module Type, Test Type, And Region.

The market size section gives the Hidradenitis Suppurativa Treatment market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Hidradenitis Suppurativa Treatment industry over a defined period.

Download Full PDF Sample Copy of Report:

Key Manufacturers of Hidradenitis Suppurativa Treatment Market include: GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Allergan, AstraZeneca, … Hidradenitis Suppurativa Treatment

The research covers the current market size of the [Global Hidradenitis Suppurativa Treatment Market Size, Status and Forecast 2020-2026] and its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc.,. The in-depth information by segments of Hidradenitis Suppurativa Treatment market helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the [Global Hidradenitis Suppurativa Treatment Market Size, Status and Forecast 2020-2026].

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of [Global Hidradenitis Suppurativa Treatment Market Size, Status and Forecast 2020-2026]. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Read Detailed Index of full Research Study:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Hidradenitis Suppurativa Treatment in these regions, from 2012 to 2022 (forecast), covering

Please Check below Chapters to display the [Global Hidradenitis Suppurativa Treatment Market Size, Status and Forecast 2020-2026].

There are 15 Chapters to display the [Global Hidradenitis Suppurativa Treatment Market Size, Status and Forecast 2020-2026].

Request for customization in Report and get it within 24 hours in your inbox:

Table of Contents:

Chapter 1, to describe Definition, Specifications and Classification of Hidradenitis Suppurativa Treatment, Applications of Hidradenitis Suppurativa Treatment, Market Segment by Regions;

Chapter 2, To analyse the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Hidradenitis Suppurativa Treatment, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Allergan, AstraZeneca, … Hidradenitis Suppurativa Treatment ), Sales Analysis (GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Allergan, AstraZeneca, … Hidradenitis Suppurativa Treatment ), Sales Price Analysis (GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, AbbVie, Allergan, AstraZeneca, … Hidradenitis Suppurativa Treatment );

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Hidradenitis Suppurativa Treatment Segment Market Analysis;

Chapter 7 and 8, to analyse the Hidradenitis Suppurativa Treatment Segment Market Analysis Major Manufacturers Analysis of Hidradenitis Suppurativa Treatment;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend;

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyse the Consumers Analysis of Hidradenitis Suppurativa Treatment;

Chapter 12, to describe Hidradenitis Suppurativa Treatment Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Hidradenitis Suppurativa Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.



Source link